WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014187807) FOLLISTATIN DERIVATIVES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/187807    International Application No.:    PCT/EP2014/060312
Publication Date: 27.11.2014 International Filing Date: 20.05.2014
Chapter 2 Demand Filed:    03.10.2014    
IPC:
A61P 19/10 (2006.01), A61K 38/17 (2006.01)
Applicants: ARCARIOS B.V. [NL/NL]; Dr. Molewaterplein 40 NL-3015 GD Rotterdam (NL)
Inventors: DE WILDE, Gert; (BE).
EIJKEN, Hermanus Johannes Marco; (NL)
Agent: DELTAPATENTS B.V.; Fellenoord 370 NL-5611 ZL Eindhoven (NL)
Priority Data:
13168577.8 21.05.2013 EP
Title (EN) FOLLISTATIN DERIVATIVES
(FR) DÉRIVÉS DE FOLLISTATINE
Abstract: front page image
(EN)The present invention relates to a recombinant human follistatin polypeptide in which the heparin binding sequence (HBS) in follistatin domain FSD1 is replaced by a corresponding non-heparin binding motif from follistatin domain FSD2for the treatment of bone related disorders. The polypeptide of the invention originates from the longer 315 residue containing splice variant of human follistatin that, in contrast to the shorter 288 residue containing splice variant, is able to stimulate bone formation in vivo upon parenteral, intravenous, intraperitoneal or intracapsular administration.
(FR)La présente invention concerne un polypeptide de follistatine recombinant dans lequel la séquence de liaison d’héparine (HBS) dans le domaine de follistatine FSD1 est remplacée par un motif non-liaison d’héparine du domaine de follistatine FSD2 pour le traitement de troubles liés aux os. Le polypeptide de l’invention provient du variant d’épissage plus long contenant 315 résidus de folistatine humaine qui, contrairement au variant d’épissage plus court de 288 résidus, est capable de stimuler la formation d’os in vivo après administration parentérale, intraveineuse, intrapéritonéale ou intracapsulaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)